Archive for the ‘Articles’ Category

UNMC/Nebraska Medicine named national Ebola training, education center


UNMC/Nebraska Medicine, in collaboration with Emory University in Atlanta and Bellevue Hospital Center in New York City, have been awarded a $12 million grant by the U.S. Department of Health and Human Services (HHS) to establish and co-lead the nation’s National Ebola Training and Education Center (NETEC).

The three institutions will partner with the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) and the Centers for Disease Control and Prevention (CDC) to support the training of health care providers and facilities on strategies to manage Ebola and other emerging infectious diseases.

UNMC and its primary clinical partner, Nebraska Medicine, will receive $5.1 million of the $12 million federal grant – the largest share of the three collaborating institutions.

Regional Ebola treatment center 

UNMC/Nebraska Medicine is one of nine regional Ebola treatment centers recently named by HHS as part of a national network of 55 Ebola treatment centers with enhanced capabilities to treat patients with confirmed Ebola or other highly infectious diseases.

Ebola treatment centers are staffed, equipped and have been assessed to have current capabilities, training and resources to provide the complex treatment necessary to care for a person with Ebola while minimizing risk to health care workers.

“We are pleased to receive this designation as a national leader in the world’s fight against Ebola and other infectious diseases,” said Jeffrey P. Gold, M.D., UNMC chancellor and board chairman for UNMC’s clinical partner, Nebraska Medicine. “Our campus is in this position because we have selfless, talented individuals who prepared for a decade to care for the sickest of patients in our biocontainment unit. They did so valiantly over several months in 2014, and they also have shared their expertise to train countless others from around the world in preparation for the next highly infectious disease outbreak.

“I also want to thank our state’s congressional delegation for their support and work in helping us receive this significant designation.”

During the Ebola outbreak of 2014, UNMC/Nebraska Medicine was recognized as a national asset and referred to as the “gold standard” for treatment and development of safety protocols to handle Ebola and highly infectious diseases.

UNMC/Nebraska Medicine has the largest operational biocontainment unit in the nation.

UNMC/Nebraska Medicine and Emory University have worked with the CDC since December to train more than 460 health care workers from 87 health care systems, including 37 designated Ebola treatment centers, on all aspects of infection control and patient care for individuals with Ebola.


Philip Smith, M.D., medical director of the Nebraska Biocontainment Unit at Nebraska Medicine and professor, UNMC College of Public Health, is principal investigator of the UNMC/Nebraska Medicine grant from HHS.

UNMC and Emory are offering additional training opportunities this summer for up to 400 staff from Ebola assessment hospitals.
The new National Ebola Training and Education Center will expand on the success of this initial work and offer state health departments and health care facilities additional access to the clinical expertise and training capabilities offered by these institutions.

“The national center contributes to our nation’s health security by developing and teaching evidence-based practices of experienced providers and health care institutions in caring for patients with Ebola and other serious infectious diseases,” said Nicole Lurie, M.D., assistant secretary for preparedness and response for HHS. “While this training starts with Ebola, it also will help the health care community deal with other serious infectious diseases in the future.”

CDC Director Tom Frieden, M.D., said the ongoing Ebola epidemic in West Africa is proof “that a threat anywhere can be a threat everywhere; the United States must continue to prepare.

“Hospitals are often the first place where a new disease threat is recognized. This new center will help our hospitals and health care workers prepare to handle new threats and safely care for patients.”

Hyperbaric Oxygen Therapy Can Reverse Radiation Induced Vascular Injury

Hyperbaric oxygen therapy (HBO) has become an important treatment to reduce the uncommon but serious, late affects of radiation therapy.

“About one in 20 people will experience the late affects of radiation therapy and experience microvascular loss in that area,” says Jeffrey Cooper, MD, emergency specialist and medical director of the Hyperbaric Medicine Center at Nebraska Medicine. “We typically see an 80 to 85 percent success rate depending on the condition and how soon we see the patient. The longer the problem goes on before we treat the patient, the more difficult it is to treat the tissue.”


Jeffrey Cooper, MD
HBO, which has been available at Nebraska Medicine since the mid-1980s, involves breathing 100 percent oxygen in a sealed chamber under pressure to treat a variety of disorders, including carbon monoxide intoxication, decompression sickness, diabetic wounds, air emboli and life-threatening processes including gas gangrene and other necrotizing infections.

By delivering oxygen at two to three times normal atmospheric pressure, the therapy works by forcing more oxygen into areas that aren’t getting adequate amounts due to tissue damage or swelling. This increases the oxygen concentration in the blood and body tissues, which promotes healing. It also helps revive the immune system and helps the antibiotics work more effectively.

HBO treats the delayed side effects of radiation therapy by reversing the radiation-induced vascular injury to affected bone and soft tissues. During radiation, many of the smallest of blood vessels may be damaged or destroyed, which then limits the access of ingredients necessary for healing such as oxygen, antibiotics, nutrition, vitamins and growth factors.

One study showed that when hemorrhagic cystitis was treated within the first six months, the success rate was nearly 100 percent, says Dr. Cooper. The success rate for patients who were treated after six months dropped to 66 percent.

“Necrosis tends to be progressive and many tissues won’t heal even with surgical intervention,” he says. “The key is to reverse the necrotic process so the body can start to heal itself again. If we see the patient early enough, we can sometimes reverse the process without surgery. While some patients may still need surgical intervention, the patient will likely require less aggressive surgery and it will be more successful.”

Treatment for osteoradionecrosis typically requires 30 to 40 two-hour daily treatments, notes Dr. Cooper. An additional 10 treatments may be required after surgical interventions.

Head and neck cancers are some of the most common cancers that lead to osteoradionecrosis. Other common cancers in which treatment can lead to radiation injury include bladder, bowel, jaw and skin cancers.

HBO has also become an important therapy in treating hard-to-heal diabetic wounds, anemia, and problem flaps or grafts from plastic surgery. Head and neck surgeons at Nebraska Medicine have also seen success in promoting healing for various soft tissue and bone restorative and reconstructive procedures.

Nebraska Medicine is the only hospital with a 24/7 Hyperbaric Oxygen Unit that can treat acute and critically ill patients in the area. Acute cases include patients with gas gangrene, necrotizing fasciitis, carbon monoxide poisoning, crush injuries to the limbs and those suffering from diving accidents. The unit now houses four monoplace (one person) chambers in total.

“HBO is an adjunctive treatment that can change a person’s odds,” says Dr. Cooper. “It is most often used in combination with antibiotics and surgery, and if we see the patient early enough, it can stack the deck in a person’s favor. We’re seeing a marked reduction in morbidity and mortality in patients whom we treat. We’re seeing fewer complications and in some cases, it can mean the difference between an amputation and saving a limb. The key to its success is getting the patient to us before things get out of control. HBO can salvage at risk tissue, but it can’t recover lost tissue.”

New Lung Transplant Program Expected to Begin Early Summer

Providers anticipate 10 lung transplants in the first year, increasing to 35 to 40 by the third year.

One of the biggest supporters of the new lung transplant program is Heather Strah, MD. As director of Lung Transplantation, she plays an integral role in the planning process.

Heather Strah, MD
“There is definitely a need for a lung transplant program in this area,” says Heather Strah, MD, director of Lung Transplantation at Nebraska Medicine. “The nearest programs are almost 400 miles away. This creates quite a burden on the patient and family who must relocate for three months or more during the transplant process. Some patients are turned down because they are not able to relocate.”

Dr. Strah completed medical school at the University of Iowa Carver College of Medicine in Iowa City, an internal medicine residency at the University of Pittsburgh Medical Center and a pulmonary and critical care medicine fellowship at Washington University School of Medicine-Barnes Jewish Hospital. She also completed a post-doctoral research fellowship at Washington University School of Medicine in immunology. Washington University has one of the oldest lung transplant programs in the country and performs nearly 60 lung transplants annually.

Other members of the lung transplant team thoracic and cardiac surgeons Michael Moulton, MD, and Aleem Siddique, MD.



Approximately 1,800 transplants are done in the United States each year. Thirty-five percent of these patients have end-stage chronic obstructive pulmonary disease (COPD), 15 percent have cystic fibrosis and 30 percent have interstitial lung disease or idiopathic pulmonary fibrosis. The remaining 20 percent have other conditions such as pulmonary hypertension or sarcoidosis.

Each patient must go through a thorough evaluation and screening process to make sure he or she is a good candidate. Lung transplants are generally reserved for individuals whose lung disease is in the most advanced stages and they are likely to die of their lung disease within one to two years despite maximal medical therapies, notes Dr. Strah. Good transplant candidates are in generally good health, other than their lung disease, and have a good support system.

Lung transplants are usually performed on patients between the ages of 16 to 65. Younger patients typically fare the best, says Dr. Strah. Survival for the first year is 80 percent. Five years out, half of patients will have died due to complications related to the transplant.

“For those who have good outcomes, a lung transplant can be a life-changing experience,” she says. “I have seen patients who have been living 20 years or more with their transplant.”

Dr. Strah stresses the need to refer potential candidates early on. About half the people on the waiting list receive a transplant within a year.

“There is no such thing as a referral that is too early,” notes Dr. Strah, “but there are definitely referrals that come too late. The lung is a fragile organ and it can take a long time to find a suitable donor so early referral is best.”

To contact Dr. Strah or request a referral, please call the clinic at (402) 559-4015.

Letter from the Director | Fred & Pamela Buffett Cancer Center


Today we stand at the forefront of a revolutionary period for cancer research and patient care. For the very first time in history, we have the opportunity to uncover the mystery of cancer. These new findings promise to unlock our understanding of this deadly disease and forever change the way we administer treatment. Very soon, we will no longer treat cancer types but instead, personalize treatment by targeting specific gene mutations.

The Fred & Pamela Buffett Cancer Center is poised to take the lead in this effort – on a regional, national and international front. But to get there, we need to work together.

The culture of the new cancer center is defined by the idea that unplanned collaboration sparks discovery. The kind of magic where the stars align and everything falls into place.


We are establishing a commitment to collaboration where the world’s best doctors and researchers ask questions, share ideas and find answers that profoundly improve patient outcomes. Here, science and medicine will align in new and uncharted ways.

Every square inch of the Fred & Pamela Buffett Cancer Center has been designed with this philosophy in mind. The physical layout will foster a new way of “doing” cancer research and care by breaking down the divisions and silos that have separated scientists and clinicians in the past.

The new Fred & Pamela Buffett Cancer Center wants to be something different, something out of the ordinary. Extraordinary patient care and scientific advancements will take place together, creating a synergistic precision that represents the future of medical care. Science and medicine will share not just a common space, but also a common goal.

For too long, the approach to treating cancer has been indiscriminate and lacking in precision. To kill the bad required physicians to also kill the good. It’s part of the reason cancer is so scary. Not just the disease itself, but because the treatments available cause significant damage and debilitation. Today we have the opportunity to discard the “one size fits all” treatments and develop and employ targeted, less toxic, more humane therapies.

The Fred & Pamela Buffett Cancer Center will bring together elements that aren’t commonly associated with cancer care, including music and fine art, meditation and yoga. Our team will aggressively work to cure disease of the body while recognizing the human mind and spirit play an integral role in the healing process. This integrated approach to medicine will help patients and their families deal with the challenges associated with cancer in an atmosphere that breeds hope, optimism and resilience.

The heroism found in each patient is the foundation from which we will build this great new center.

This is how I know we will succeed.

Because it’s personal.




Kenneth H. Cowan, MD, PhD

Director, Fred & Pamela Buffett Cancer Center

Russian researchers/physicians learn about UNMC

by Tom O’Connor, UNMC public relations

Members of the Russian delegation included (left-right) Ludmila Annable (translator), Aleksandr Khilkov (facilitator), Danielle Dohrmann, director of program development, international health and medical education and one of the UNMC hosts of the group, Kira Ageyeva, Dmitriy Kolpakov, Ward Chambers, M.D., executive director, international health and medical education and one of the UNMC hosts of the group, Dmitriy Kireyev, Anastasiya Pokrovskaya, Georgiy Yefimov, Maria Cochran (translator), and Konstantin Mironov.

A group of six Russian researchers/physicians spent three days at UNMC this week as part of the Open World Program, one of the most effective U.S. exchange programs for countries of the post-Soviet era.

“I think it was a very worthwhile visit,” said Ward Chambers, M.D., executive director, international health and medical education for the UNMC College of Public Health and one of the UNMC hosts for the group. “Russian scientists are just like scientists all over the world. When you’re dealing with other scientists, the politics between the two countries doesn’t matter. They are far more interested in knowledge than politics.”

The Russian delegation met with more than 20 UNMC administrators and faculty between Monday and Wednesday, including UNMC Chancellor Jeffrey P. Gold, M.D. They gained exposure to a variety of different areas, including organ transplantation, nanomedicine, HIV research, DNA sequencing, and human genetics.

“They were particularly interested in our HIV research, as infectious diseases and HIV are the focus of much of their work,” Dr. Chambers said. “It also was nice that some of our researchers were able to speak Russian with them.”

The Open World Leadership Center administers the Open World program. Begun as a pilot program in 1999 and established as a permanent agency in late 2000, the center conducts the first and only international exchange agency in the U.S. legislative branch.

It has enabled more than 17,000 current and future leaders from Azerbaijan, Georgia, Kazakhstan, Kyrgyzstan, Moldova, Russia, Ukraine, Tajikistan, and Turkmenistan to meaningfully engage and interact with members of Congress, Congressional staff, and thousands of other Americans, many of whom are the delegates’ direct professional counterparts.

The Open World program focuses both on assisting Congress in its oversight responsibilities and on conducting exchanges that establish lasting professional relationships between the up-and-coming leaders of Open World countries and Americans dedicated to showcasing U.S. values and democratic institutions.

Open World delegations consist of committed leaders (average age 38) who experience in-depth programming in themes of interest to Congress and of transnational impact.

Former U.S. Sen. Ben Nelson was instrumental in bringing the exchange program to Nebraska, Dr. Chambers said. Because of this, the Russian visitors are known as Ben Nelson Fellows.

Two prominent Nebraska business leaders and longtime supporters of UNMC, Mike Yanney and Walter Scott, are members of the Open World Leadership Center Board of Trustees. Scott is chairman of the board, while Yanney is chairman emeritus. Rep. Jeff Fortenberry of Nebraska also is a member of the board.

Dr. Green’s research led to lymphoma breakthrough

by Kalani Simpson, UNMC public relations

Michael Green, Ph.D., assistant professor in the Eppley Institute,
A new recruit to the Fred & Pamela Buffett Cancer Center begins his UNMC career on the heels of a major contribution to a breakthrough in Hodgkin’s lymphoma treatment.

Clinical trial results for the new therapy inspired by his research were detailed in a December 2014 edition of The New England Journal of Medicine.

Michael Green, Ph.D., assistant professor in the Eppley Institute, while a postdoc at Dana-Farber Cancer Institute in Boston in 2010, was first author on the discovery of a therapy target — a gene whose increased expression allowed cancer cells to evade being seen and eradicated by the immune system.

Expression of this gene may be why Hodgkin’s relapse rates can be as high as 25 percent.

“It’s a ligand on the tumor cell surface that binds to a receptor on the T-cell and tells them not to perform their normal function,” Dr. Green said. “Its natural role in biology is after an infection to try and bring down the immune response after the infection has been cleared. But it has been hijacked by these cancer cells so they can shut down an anti-tumor immune response.”

Thankfully, there was a potential neutralizing antibody already in clinical trials. So a study involving patients with relapsed or refractory lymphoma got to skip straight to Phase II, to “a pretty remarkable result,” Dr. Green said. The treatment was awarded breakthrough therapy (BT) designation by the FDA. Dr. Green had already left for Stanford University by the time the clinical trial started, but feels very satisfied with the end result.

“That’s why we do what we do,” he said. “Publications and grants are nice but this is the real reason behind our research.”

At Stanford, Dr. Green turned his attention to the as-yet incurable follicular lymphoma. And there is no better place to continue this research, he decided, than at UNMC, where Jim Armitage, M.D., and Julie Vose, M.D., head up a world-renowned lymphoma study group.

“That was imperative in coming here,” he said. “I’m doing a lot of next-generation sequencing and there’s a genomics core here. I do a lot of immunology and there’s a very good flow cytometry core here. And the biggest thing really is a massive bank of tumors here.”

And the relationship history with the patients who gave them.

Now, Dr. Green is studying a novel gene mutation which helps follicular lymphoma cells evade the immune system. “We have defined the mutation we want to target, so now we are trying to identify a specific therapy — it is a great example of ‘precision medicine.'”

New insights in lung cancer treatment


In the past decade, we’ve come a long way in our knowledge of lung cancer. Until then, we had only a basic understanding of the tumor cells – and chemotherapy helped only a small percentage of patients.

We knew very little about lung cancer cells. We only knew about “small cell lung cancer” and “non-small cell lung cancer,” which basically was everything else. Today, from 10 to 15 percent of lung cancers are the small cell type.

We knew there were differences among these “non-small cell” cancers. But we didn’t have the tools to identify them, and we didn’t know how to treat them. Everyone got the same chemotherapy treatment, which was very effective in some cases – but not for many.

That changed when drug called Iressa was introduced in the U.S. This drug helped a small minority of patients – and they responded dramatically. Their tumors disappeared in a matter of weeks. Unbelievable!

This led to research to find out more about these patients. This also started a revolution in understanding different sub-types of non-small cell lung cancer. Today, using sophisticated tests, we can identify the main mutation causing lung cancer in a significant proportion of patients.

This research has led to targeted treatments we use today, with much greater success. New drugs have been developed to treat two of these lung cancer sub-types. These drugs primarily help people who have not been smokers – but have developed lung cancer from other toxic exposures, like radon.

Erlotinib, Afatinib, Pemetrexed, Crizotinib and Ceritinib are drugs that that we use today – to treat some of these specific types of lung cancer. Many of these drugs and others like these are still in clinical trials, to study their effectiveness. While we still don’t have all the answers, and still don’t have drug treatments that help everyone, we’ve come a very long way.

Several more medications are in clinical trials. We’re continually looking for more answers, trying to help many more lung cancer patients. But our progress in the past 10 years has given all lung cancer patients – and medical specialists like me – more hope.

At Nebraska Medicine, our service is designated by the National Cancer Center as a Lung Cancer Alliance Screening Center of Excellence. This reflects our team’s experience as well as our multidisciplinary program in managing patient care.

With this level of expertise, you will receive the treatment that specifically targets your lung cancer sub-type. We’ll stay with you every step of the way, making sure you’re getting excellent care.

Take heart that, when your cancer is caught at an early stage, you stand a very good chance of cure. The American Cancer Society reports that over 430,000 people alive today have been diagnosed with lung cancer at some point.

A Transplant’s Not the Only Alternative for Children With Intestinal Failure; Rehab is an Option for Most Patients


Our intestinal transplant program has a worldwide reputation. We’ve performed more intestinal transplants here at The Nebraska Medical Center than any other single hospital in the world. We helped pioneer the procedure.

But whenever possible we prefer not to do it.

Rehab for our pediatric intestinal failure patients is so successful, we don’t need to transplant very often. Rehab has become our default – with transplant as a wonderful backup plan, but no longer the only option.

Our patients come from all over the country and around the world. Many times, parents have been told that an intestinal transplant is the only treatment for their child. But when they arrive, we start with what they have – whatever the child’s condition and function – and go from there. It’s better to build on whatever they have than to start over. The family goes from having no hope to realizing that, very likely, their child will be able to live and eat normally.

When a child comes to our program, the family needs to be here four to six weeks. That sounds like a long time at first. But once they arrive, the families are so relieved and comfortable, often they don’t want to leave. Regardless of when they return home, they are part of the program for life.

Here’s what usually happens. The first week is evaluation with testing every day, and we make a plan. Next is an inpatient stay for a surgical intervention. Then it’s outpatient care for the next few weeks, attending weekly clinics and communicating almost daily with our team as we work on improving function in the intestinal tract, finding a pathway that will work for them and carefully moving toward our goal of eating and drinking by mouth.

When I tell parents that we hope their baby will one day go to kindergarten, carry a lunchbox to school and eat just like other kids, it blows their minds. But that is the goal, and we see our patients reach it all the time. It takes time and a dedicated team of experts guiding the way, but we get there working together. The family has been told to expect the worst; we let them know to expect the best.

There are times when we meet a child and we decide that the risks of taking time to work on intestinal rehabilitation are too high – that perhaps there has been too much damage done prior to their arrival.  There are other times when, despite everything we do, we cannot make progress and the risks of being on TPN begin to mount. These are the times when we turn to transplant, and in these cases it is truly lifesaving.

Rehabilitation and transplantation aren’t competitors with each other, but rather they work together so the right thing can be done for a child at the right time. When we can, we always prefer rehab, because successful intestinal rehabilitation doesn’t just delay the need for a transplant – it eliminates it.  When that goal can’t be achieved, transplant moves in to provide lifesaving therapy.

With these two complementary tools, the child with intestinal failure has a great chance to live a full, productive life.

NICU Team Saves Baby Diagnosed With Rare Condition

Genevieve was born with a rare condition called congenital chylothorax. She was hydroptic, collecting fluid in her body tissues and around her lungs.


Genevieve was born with a rare condition called congenital chylothorax.

“The miracle on 42nd Street,” is how Genevieve Wright’s family describes their strong, resilient little girl.

On February 19th, Genevieve was born at Nebraska Medicine – Nebraska Medical Center with a rare condition called severe congenital chylothorax. She was hydroptic, collecting fluid in her body tissues and around her lungs. Only two percent of babies born with this condition survive. Most die inside the womb, or moments after birth.

“We’ve done a lot of crying and praying,” says Genevieve’s mom, Shelly Wright. “Genevieve has been in the fight of her life.”


Shelly Wright enjoys cuddling with her 2-month-old daughter, Genevieve.

Over the last two months, Ann Anderson-Berry, MD, medical director of the NICU, inserted 14 chest tubes to drain the fluids from Genevieve’s body. Some days, the NICU team removed three cups of fluid. They also worked to replenish blood and electrolytes that Genevieve was losing. Dr. Anderson-Berry says, Genevieve’s case is unlike any other documented. There were no case reports that outlined a successful treatment plan. Most days, the NICU team wasn’t sure she’d survive.

“It’s been minute to minute,” says Dr. Anderson-Berry. “But, if you look at her now, you’d never know she was so critical. Genevieve is writing her own story.”


Dr. Ann Anderson-Berry, medical director of the NICU at Nebraska Medicine, speaks with local reporters about Genevieve’s condition.

This week, Genevieve will likely be discharged and go home to join her parents and three siblings in Lincoln, Neb. She’s off the ventilator and respiratory support. She’s acting like a normal newborn, smacking her lips, smiling and scanning the room with her eyes.

“I feel like all I do is stare at her,” says Wright. “Where there’s life, there’s hope. This medical team really gave it their all. You gotta give them a chance, even the two percenters.”

Collaboration impacts personalized cancer treatment

Babu Guda, Ph.D., associate professor and director of the Bioinformatics Systems Biology Core Facility at UNMC

The Fred & Pamela Buffett Cancer Center has partnered with IBM to conduct early testing and feedback for IBM’s Watson Genomic Analytics program.

The IBM program in minutes identifies relevant mutations and potential drugs that may be considered in a treatment regime — all based on the patient’s genomic profile and the specific mutations.

The Fred & Pamela Buffett Cancer Center at UNMC and Nebraska Medicine in Omaha, is one of 14 leading cancer institutes to partner on the project, which is part of IBM’s broader Watson Health initiative to advance patient-centered care and improve health while building on IBM research advancements.

Most of the 1.6 million Americans who are diagnosed with cancer each year receive standard treatment. When standard treatment fails and with genetic sequencing becoming increasingly accessible and affordable, some patients are beginning to benefit from treatments that target their specific cancer-causing genetic mutations.

Babu Guda, Ph.D., associate professor and director of the Bioinformatics Systems Biology Core Facility at UNMC, will be collaborating with Ken Cowan, M.D., Ph.D., director of the Fred & Pamela Buffett Cancer Center and breast cancer physician, to analyze cancer tumor genomes on the project.

“IBM has fed millions of research articles into the program, including biomedical research and clinical information,” Dr. Guda said. “The cognitive computer can keep track of the complex relationships among gene mutations, drug treatments and treatment outcomes.”

IBM describes cognitive computing as computers that learn and interact naturally with people to extend what either humans or machines could do on their own to help human experts make better decisions.

With each patient, the cancer center team is sequencing the genomes of normal and tumor tissues and identifying variations that are specific to the tumor tissues. Tumors can have many mutations, but some — “driver mutations” — are critical for the initiation and progression of cancer.

“Typically, we get several thousands (of variations),” Dr. Guda said. “Not every change is important, but some driver mutations or other serious mutations that alter cellular function may give a selective advantage for cancer cells to proliferate and spread the disease to distant locations,” he said.

Steve Harvey, vice president, IBM Watson Health, said Watson will help deliver personalized cancer care using the latest advances in science by integrating complex and disparate data in a cognitive system. “Ultimately, our goal is to create a solution that any oncologist in any location can use to identify personalized treatment options for their patients.”